Author + information
- Received May 30, 1990
- Revision received September 11, 1990
- Accepted September 24, 1990
- Published online March 15, 1991.
- Anne M. Gillis, MD, FRCPC∗,1,
- D.George Wyse, MD, PhD, FRCPC, FACC2,
- Henry J. Duff, MD, FRCPC3 and
- L.Brent Mitchell, MD, FRCPC4
- ↵∗Address for reprints: Anne M. Gillis, MD, Department of Medicine, 3330 Hospital Drive, NW, Calgary, Alberta, Canada T2N 4NI.
The clinical and electrophysiologic predictors of successful antiarrhythmic drug therapy for patients with inducible ventricular tachycardia were evaluated in 59 consecutive patients undergoing serial electropharmacologic trials. Structural heart disease was less frequently present in patients for whom effective therapy was found (p < 0.05). The presence of coronary artery disease and a history of prior myocardial infarction were significantly more frequently present in patients for whom antiarrhythmic drug therapy could not be found (p < 0.05). The corrected QT interval and ventricular effective refractory period measured at a pacing cycle length of 400 ms were significantly shorter in responders compared with nonresponders (QT interval 428 ± 52 versus 460 ± 59 ms; ventricular effective refractory period 237 ± 28 versus 254 ± 24 ms; (p < 0.05). In addition, the interelectrogram coupling interval of the ventricular extrastimulus initiating ventricular tachycardia was significantly shorter in responders compared with nonresponders (223 ± 37 versus 251 ± 33 ms; p = 0.003).
Logistic regression analysis identified a short ventricular inter-electrogram coupling interval (p < 0.01) end absence of prior myocardial infarction (p < 0.05) as the only independent predictors of antiarrhythmic drug suppression of the induction of ventricular tachycardia. Greater drug-induced increments in the ventricular effective and functional refractory periods were observed in responders than in nonresponders as was the shortest ventricular interelectrogram coupling interval.
Thus, baseline electrophysiologic measurements identify patients with inducible ventricular tachycardia who are likely to respond to antiarrhythmic drag therapy. Furthermore, these patients demonstrate greater drug-induced electrophysiologic changes.
↵1 Dr. Gillis is a Clinical Investigator.
↵2 Dr. Wyse is Scholar of the Alberta Heritage Foundation for Medical Research.
↵3 Dr. Duff is Scholar of the Alberta Heritage Foundation for Medical Research.
↵4 Dr. Mitchell is Scholar of the Alberta Heritage Foundation for Medical Research.
☆ This study was supported by grants from the Alberta Heart and Stroke Foundation, Calgary, Alberta, Canada and the Alberta Heritage Foundation for Medical Research, Edmonton, Alberta.
- Received May 30, 1990.
- Revision received September 11, 1990.
- Accepted September 24, 1990.